Every MedTech company I talk to about entering the Nordics has the same story. They found a distributor — usually the first one that replied — signed a three-year exclusive contract, and eighteen months later they realise the contract they signed is the reason sales aren't growing.
The contract was not aggressive. It was not badly drafted. It simply reflected what the distributor wanted and what the manufacturer did not know to ask for. That's the actual asymmetry in Nordic MedTech market entry: the distributor has negotiated dozens of these agreements, and the manufacturer — if this is their first Nordic launch — has negotiated one.
Over the last nine years running a Swiss precision medical device manufacturer's commercial operations, I have negotiated six distribution agreements across Iberian and Nordic-adjacent markets — some that worked well, some that needed renegotiation, all of them instructive. The six red flags below are the ones I keep coming back to. None of them are unusual in isolation. They are unusual in combination, because they compound: an exclusivity without a KPI turns an ambiguous territory definition into a lock-in; a missing training clause turns a premium product into a commodity; an unclear exit turns a bad distributor into an expensive one.
Read this before your legal team redlines the draft. The clauses below sit mostly outside the usual legal review. They are commercial, operational and regulatory — and they are where manufacturers lose years.
1. Exclusivity without performance clauses
The single most expensive mistake you can make.
The distributor asks for exclusivity in "Scandinavia" or "the Nordics" for three years, minimum. That is the opening position in essentially every contract I have seen. It is also the clause most manufacturers give away for free, because exclusivity sounds like commitment on the distributor's side.
It is not. Exclusivity without a performance clause is the opposite of commitment. It is a way for the distributor to lock out other distributors without committing to anything. I have seen this go wrong twice in the same company: once in a Southern European market, once later in a Nordic adjacent market. Both times, the distributor blocked us from signing anyone else while doing the minimum amount of work to keep the territory.
The fix is not to refuse exclusivity. Exclusivity is a reasonable ask — distributors need protection to invest in a launch. The fix is to attach three things to it:
- A minimum purchase commitment, in units or revenue, measured quarterly. Under-performance triggers first a notice period, then loss of exclusivity, then termination.
- Country-level KPIs, not territory-level. If the distributor is exclusive in "the Nordics" they must hit minimum numbers in each country, not in aggregate. Otherwise Sweden carries Finland for three years.
- A market-share clause tied to your category. If you can reference a public or semi-public category tracker (and in several MedTech categories you can), use market share rather than absolute numbers. It corrects for macro.
I do not sign any exclusive agreement without a country-level KPI and a non-exclusive fallback clause that activates automatically on under-performance — with a defined notice period and a contractual cure-and-terminate path. Exclusivity has to be earned every quarter.
2. "Nordic" territory that's really just Sweden
Most pan-Nordic distributors are one country with a sales rep in another.
"Pan-Nordic" is a marketing label. Most distributors that use it are strong in one or at most two Nordic countries and maintain a skeleton presence in the others through a sales rep, a commercial agent, or — worst — a sub-distributor they have not told you about. When you sign an "exclusive Nordic agreement" you often think you have bought four-country coverage. You have bought one country plus a promise.
The giveaway is not in the marketing materials. It is in the employee distribution, the office addresses, the regulatory registrations, and who is actually on the ground at hospital tenders.
Before you sign, ask your prospective distributor these four questions and ask them to answer in writing:
- How many full-time commercial employees do you have in each of Sweden, Denmark, Norway and Finland? Not "resources." Not "coverage." Actual W-2 or local-equivalent headcount.
- In which countries are you registered as an importer under EU MDR / Norwegian Medical Devices Act? If they are not registered, they cannot legally import your product into that country.
- Which of the last 10 hospital tenders in each country did you bid on? Tender lists are public. You can verify.
- Do you use sub-distributors, and if so, in which countries and under what terms? Sub-distribution adds a margin layer and a regulatory complexity. You deserve to know.
A quick diagnostic: you can spot-check most of this against public sources. The EU MDR actor database (EUDAMED), Norwegian medical device registration, and Finnish Fimea registries all let you see whether a distributor is actually registered as an importer in each country. If they claim "pan-Nordic coverage" but only appear in one national registry, you have your answer.
I define territory country by country with separate KPIs, and I reserve the right to carve out any country where the distributor cannot demonstrate a minimum in-country team size. In practice this means I sometimes sign one distributor for Sweden and Denmark, another for Norway, and a third for Finland — because the "one pan-Nordic partner" is almost always a compromise.
3. Authorized Representative and importer conflation
A regulatory clause that blows up the first time there is an adverse event.
This is the clause legal teams miss because it sits at the intersection of commercial and regulatory. Under EU MDR (Regulation 2017/745), a non-EU manufacturer must appoint an Authorized Representative (AR) — a legal entity established in the EU that takes on specific regulatory responsibilities. Separately, the distributor who physically imports your product into an EU country is the Importer, which is a different role with different obligations.
In poorly drafted contracts, these two roles get collapsed. The distributor is named as both AR and Importer — sometimes explicitly, sometimes by implication. This is almost always against the manufacturer's interest, because:
- You lose leverage. Your AR is now your distributor. If the commercial relationship deteriorates, your distributor can, in extreme cases, threaten to withdraw from the AR role — which would immediately affect your ability to place product on the EU market.
- Post-market surveillance responsibilities blur. The AR must hold the technical documentation and cooperate with competent authorities. The Importer has different (and more limited) obligations. Contracts that merge the two create ambiguity at exactly the moment you need clarity: when there's an adverse event, a field safety notice, or a competent authority inspection.
- Switching distributors becomes a regulatory event. If your AR is tied to the distributor, terminating the distribution contract forces a change of AR, which means notifying competent authorities, updating the EUDAMED registration, and potentially informing customers.
Norway complicates this further. As an EEA member, Norway has implemented MDR via the Act on Medical Devices — but it has its own national importer registration requirement with the Norwegian Medicines Agency. Many "Nordic" contracts ignore this entirely.
The AR is a separate entity, appointed in a separate agreement, ideally independent of any single distributor. The distributor is named only as Importer, in their registered country, with explicit acknowledgement of post-market surveillance obligations and a cooperation clause. On termination, the distributor's Importer status ends; the AR agreement is unaffected.
4. No training or KOL investment obligation
The clause that quietly commoditises your premium product.
If you sell a premium, clinician-facing medical device — dental, surgical, diagnostic, anything where a physician's technique influences the outcome — your growth is tied to training. Not marketing. Training. The clinicians who use your device well become advocates; the ones who use it badly become detractors. Key Opinion Leaders (KOLs) shape adoption in their hospital and in their professional society.
Most distribution contracts say nothing about this. They talk about volume, margins, territories. They do not commit the distributor to a minimum number of training days per year, a minimum KOL investment, or a minimum share of marketing co-spend on education.
The result is predictable. The distributor's sales team pushes your product when it's easy to sell, drops it when it gets hard, and never invests in the clinical education that would make it easier. Over three years, a premium product gets positioned like a commodity because nobody committed to teaching the market why it isn't one.
I have built a distributor training-and-KOL obligation into every contract for the last six years. It is the single clause that correlates most cleanly with distributor performance in my experience.
The clause needs four elements:
- Minimum annual training days. Number depends on your category. For high-touch clinical devices I use 20 days per country per year as a floor.
- Co-funded KOL program with a minimum annual spend from the distributor side, matched or proportionate to yours. In my own program, which has 11 clinician trainers, the distributor and manufacturer both contribute — that shared commitment is what keeps the KOLs engaged when either side could walk away.
- Congress and scientific event participation — which society events the distributor commits to attend, sponsor, or present at, in each country.
- Reporting. Quarterly reporting on training delivered, KOLs active, and physician adoption measured in active users. No reporting, no accountability.
Training and KOL investment is not a "nice to have" clause tucked into the marketing support section. It is a core distributor obligation, with numbers, and it is tied to the contract's renewal and exclusivity clauses. A distributor who does not hit their training commitment loses the right to renew on the same terms.
5. Termination with no clear data and customer handover
The clause you notice three years too late.
Here is the scenario: after two or three years with a distributor, you decide to switch. Maybe growth is stalling. Maybe you want to bring the market direct. Maybe the distributor was acquired by a competitor of yours (it happens). You trigger the termination clause. Notice periods expire. You are now ready to appoint a new partner.
And then you realise you own none of the commercial infrastructure. The customer list is in the outgoing distributor's CRM. The installed base — who bought what, when, and with what service record — lives in their warehouse system. The KOL relationships are with specific sales reps employed by the exiting distributor, not by you. The post-market surveillance data is in their quality system.
All of this is recoverable, but most of it becomes a negotiation. A departing distributor has every incentive to make the handover slow, incomplete, or expensive. I have paid for this exactly once. I did not enjoy it.
The fix is a termination clause that treats data and customer handover as a contractual deliverable, not an afterthought. Specifically:
- A data ownership clause that explicitly names customer data, installed-base records, service history and complaint data as manufacturer-owned — even when the distributor holds it operationally.
- A handover protocol with defined deliverables (customer list with consent status, installed-base export, complaint and field-action log, KOL contact sheet, current tender obligations and warranties), a deadline, and a format.
- A non-solicitation clause on customers for 12 months, so the outgoing distributor cannot move the book to a competing product line.
- Continued support obligations for installed-base service during the transition, at pre-agreed rates, so you are not held hostage on warranty repairs for the first 6 months after termination.
I treat the termination and handover clause as part of the core contract — not buried in an appendix. I read it back to the distributor and ask them to acknowledge it verbally at signing. If the distributor pushes back hard on any of these four elements, that is itself a red flag about the relationship.
6. Missing minimum stock and back-order clauses
The clause that decides whether you win hospital tenders.
Nordic hospital procurement — whether via Sykehusinnkjøp in Norway, the five Danish regions plus Amgros, the 21 Swedish regional authorities, or the Finnish wellbeing services counties post-2023 reform — runs on delivery SLAs. A tender award typically specifies a delivery window: 5 working days, sometimes 10. A stock-out on a tender-awarded product is not a minor operational issue. In some framework agreements it triggers financial penalties, in others it triggers re-opening of the contract.
Your distributor's stock position is therefore your tender risk. And in many contracts, there is no minimum stock obligation at all. The distributor orders what they think they will sell, ships from what they have, and back-orders when they miscalculate. You find out about the back-order from an angry hospital procurement officer.
A well-written contract specifies:
- Minimum stock coverage — measured in weeks of forward demand or in absolute units, per SKU, per country. For tender-critical SKUs I push for 6–8 weeks.
- Back-order penalties — financial consequences for failing to fulfil against an awarded tender, independent of fault. This is the distributor's incentive to over-stock slightly rather than under-stock.
- Rolling forecast obligation — the distributor provides a 3-month rolling forecast, which becomes the basis for both stock planning and manufacturer production scheduling.
- Emergency shipment protocol — agreed in advance, with pre-agreed costs and lead times, so both sides know what happens when a back-order does occur.
A subtlety: if you are premium-priced and your product has a meaningful SKU count, stock obligations create working-capital pressure on the distributor. That is exactly the point. A distributor who genuinely believes in the product will accept reasonable stock commitments; one who does not will negotiate hard to minimise them. Watch the negotiation closely — it tells you a lot about their real commitment.
Stock, back-order penalties and rolling forecasts are in every contract I sign now. For tender-critical categories I add a specific tender-obligation clause: if the distributor is awarded a tender on my product, they take on the fulfilment liability for that tender, and I contractually support them with priority allocation if capacity gets tight.
How to use this list
The six red flags above are not independent. They interact. A weak exclusivity clause (#1) makes a vague territory definition (#2) more dangerous. A distributor who has no training obligation (#4) is more likely to under-perform, which makes the exit clauses (#5) the ones that determine how much of the next three years you waste.
If you are currently negotiating a Nordic distribution agreement, my recommendation is to read through the current draft and ask, for each of the six: what does my contract say, and what would I do if the distributor dropped the ball on this specific dimension? If your honest answer is "I would call them and ask them to do better," that is the clause that will cost you a year.
The second recommendation: distributor contracts are easier to negotiate before you need the distributor. If you have alternatives in the pipeline — and the NordicDistributors directory lists 13 vetted MedTech distributors across the four Nordic countries — you negotiate from a position of choice. If you are six months into a launch and this is the only distributor who replied to your RFP, you negotiate from a position of urgency. That difference shows up in every clause.
The cost of a bad distributor contract is not the distributor. It is the three years you lose before you can unwind it.
If you want to pressure-test a specific draft, the distributor fit scorecard on this site covers commercial dimensions but not contract-specific ones. For contract review work I do that commercially through Fractio, my Nordic-Iberian go-to-market consulting practice — typically as part of a broader Nordic market-entry engagement.